Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial Prof Georg Lenz, MDa Send email to georg.lenz@ukmuenster.de ∙ Prof Marek Trněný, MDb ∙ John M Burke, MDc ∙ Prof Grzegorz S Nowakowski, MDd ∙ Prof Christopher P Fox, MDe ∙ Annalisa Chiappella, MDf ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00866-4/fulltext?dgcid=hubspot_email_conferencealerts_asco26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-8du9f3KbFXeViPaNdIfUL7SdCGXnyCiHg-pSz23BePt35DKMTLw_zFZzAh8ID7-ybLQiWFryhUwQI5UNoVCqoXW3D49Q&_hsmi=421795296&utm_content=421795296&utm_source=hs_email